Floatz logo

2-HYDROXYOLEIC ACID (SODIUM SALT)

Glioblastoma (GBM)

Laminar PharmaceuticalsSmall moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

353 Active assets in the Glioblastoma (GBM) cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

2-HYDROXYOLEIC ACID (SODIUM SALT) is also rated in:

neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
Solid Tumor, Unspecified, ChildDormant
CCC
Indicative ·
48 / 100
View asset →
malignant gliomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →